juva cbdDecember 15, 2021
Through the Company’s research division, Juva has already identified two proprietary compounds they believe may hold this potential: JUVA-019 and JUVA-041. Inflammation is a response in the body to signal potential danger or damage to organs. Inflammation can be either short-lived (acute) or long-lasting (chronic), with underlying triggers such as cancer, heart disease, asthma, and arthritis. According to recent estimates by Rand Corporation , in 2014 nearly 60% of Americans had at least one chronic condition, 42% had more than one and 12% of adults had 5 or more chronic conditions causing inflammation — and worldwide, 3 of 5 people die due to chronic inflammatory diseases. The global anti-inflammatory therapeutics market is estimated to reach USD $191.4 billion by 2027, as reported by Fortune Business Insights .
Vancouver, British Columbia, CANADA.
Doug Chloupek, CEO and Founder.
Cannabis and Life Sciences Company Initiates Internal Study Comparing Anti-Inflammatory Properties of Candidate JUVA-019 When Combined With Cannabinoids Such as THC and CBD.
Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.
The study will be conducted in-house via Juva’s research team, led by Dr. Sanjeev Gangwar, Ph.D., who has an extensive background in pharmaceutical research and development. The study will follow a similar protocol used previously to identify JUVA-019. JUVA-019 will be evaluated in combination with multiple well-known cannabinoids, one at a time, and then all together to evaluate their inhibition of IL1-beta and TNF-alpha, which are some of the biomarkers in the body that indicate inflammation. The results will then be compared to the results from JUVA-019, identifying which combination or standalone compound is more effective at inhibition of multiple cytokines implicated in inflammation.
November 30, 2021 04:00 ET | Source: Juva Life Inc. Juva Life Inc.
Tel: +1 833-333-5882 (JUVA)
About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)
Where many companies are conducting researching on well-known cannabinoids such as CBD and THC, Juva has identified two proprietary, non-cannabinoid compounds, JUVA-019 and JUVA-041, with potentially greater anti-inflammatory properties than cannabinoids. The goal of the announced study will be to combine JUVA-019 with popular cannabinoids such as CBD and THC and to evaluate the anti-inflammatory properties when combined versus as a standalone compound.
Forward Looking Statement.
Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/ .
Juva Life Investor Relations.
ON BEHALF OF THE BOARD,
VANCOUVER, British Columbia, Nov. 30, 2021 (GLOBE NEWSWIRE) — Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life sciences portfolio company with operations in cannabis production and distribution as well as pharmaceutical research and development, announced today that it has launched a pre-clinical comparative study on its proprietary molecular candidate JUVA-019, comparing its anti-inflammatory properties as a standalone compound and in combination with well-known cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD). The goal of the study is to determine if Juva will advance JUVA-019 as a standalone compound, or if it will combine with other cannabinoids as a drug candidate with anti-inflammatory properties.
For further information, please contact:
This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.
“This is an important step in the research protocol of our pharmaceutical program on JUVA-019,” said Doug Chloupek, CEO and Founder of Juva. “It’s widely believed that in order for cannabis to be effective as an anti-inflammatory, all of the cannabinoids found in the plant must be present, creating what is known as the Entourage Effect. While there is plenty of anecdotal evidence that cannabis holds anti-inflammatory properties, the true cause of the mode of action remains unknown. Our mission is to research this very question and identify compounds within the plant that cause a positive reaction in reducing inflammation in the body.”
The CSE does not accept responsibility for the adequacy or accuracy of this release.
General Information 🕒 Operating hours: Tuesday – Saturday from 10 am – 8 pm 📍 Location: Java Studios 👤 Age requirement: All ages 📱 Next steps: A reservation is required—please find further reservation details in the instructions section of your Fever ticket.
Description Cannabidiol (CBD) is a non-psychoactive cannabis compound with natural anti-inflammatory, pain-relieving, and nerve-calming properties. Reclaimed Being’s CBD-Infused Massage incorporates pure CBD oil extracted from hemp plants. CBD’s direct penetration through the skin allows for added effectiveness in isolated pain management of the muscles and joints and will also accelerate the recovery and healing process for any injured connective tissue. Book a CBD-infused treatment today to take the next step in reclaiming your being!
By now, you’ve probably heard about the benefits of cannabidiol (CBD). The non-intoxicating compound found in cannabis and hemp has been found to have an array of therapeutic benefits, from suppressing seizures and reducing inflammation to calming anxiety and decreasing depression.
There are two types of CBD available. CBD derived from the hemp plant contains less than 0.3% THC, which won’t get you high. Although hemp is now legal at the federal level, different states have their own legislation regarding CBD oil. Cannabis-derived CBD offers a higher THC content (between 5% and 30%) and is only available in states where cannabis has been legalized for medical or recreational use.
Where cannabis is legal for medical or recreational use, products are heavily regulated and must undergo stringent testing from licensed facilities. For example, in California, all cannabis must be tested for the presence of:
Hemp-Derived CBD vs. Cannabis-Derived CBD.
Unfortunately, the CBD you find at retail shops is often made with synthetic additives that don’t meet testing standards. Even worse, some of this CBD oil contains only trace amounts of cannabidiol. After the U.S. Farm Bill passed in 2018 that legalized industrial hemp, the CBD market exploded. Because CBD is not yet bound by government regulations, the market has become flooded with shady businesses looking to capitalize on its popularity.
Another main difference between the two types of CBD is oversight. Hemp-derived CBD is not yet subject to a widely enforced regulatory framework. This is why you see products being sold in grocery stores and gas stations.
The CBD craze has reached every corner of America. But as you might suspect, the CBD body oil gifted to guests at a celebrity wedding shower is vastly different from the CBD oil you’d find on the shelves of your neighborhood convenience store. What about a middle ground – CBD that actually makes you feel better?
How can you make sure you’re getting the best medicinal product for your money? We explain the differences between products, and what to look for in your search for relief.
Certain types of hemp-derived CBD do contain cannabinoids and terpenes. But these extractions have neither the concentration nor the diversity of the healing compounds found in marijuana plants. The lower potency of THC in hemp-based CBD makes the extract is less effective for treating certain symptoms, such as pain and inflammation.
But not all CBD in the marketplace is snake oil. In fact, the highest quality cannabidiol has had profound medicinal benefits, from helping sick children become seizure-free to easing cancer symptoms and maximizing quality of life for elderly consumers.
Testing Weeds Out the Snake Oil and Keeps You Safe.
At the molecular level, CBD is the same compound regardless of whether it’s found in a hemp or cannabis plant. The primary difference lies in the source. CBD from cannabis contains a richer variety of cannabinoids due to its resin (the sticky crystals that appear on female cannabis flowers). The range of beneficial cannabinoids and terpenes – the aromatic oils that give cannabis its distinct flavors and aromas – work together to create something called the entourage effect. It’s this phenomenon, say experts, that gives whole-plant cannabis extracts greater therapeutic benefits than their hemp counterparts.
Each product is also tested for its cannabinoid and terpene content, so consumers know exactly what they’re putting into their bodies. Some hemp CBD companies perform their own third-party testing to check for the presence of metals, pesticides and other toxins. No matter what kind of CBD appeals to you, be sure to look for test results.